GlassScriptPhysician profile
Amir Alamir
NPI 1386633667
$1,264.28
in general payments reported to CMS, 2019-2025
13 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $145 · 2021: $46.00 · 2022: $355 · 2023: $49.35 · 2024: $148 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314 · Education: $34.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.29 |
| Education | $34.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $345.37 | 2019-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $289.83 | 2019-2021 | |
| Abbott Laboratories | $119.15 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $102.16 | 2019 | |
| Glaxosmithkline, LLC. | $99.39 | 2022 | |
| Gilead Sciences, INC. | $88.76 | 2023-2024 | Veklury |
| Fresenius USA Marketing, INC. | $62.45 | 2025 | Velphoro |
| Regeneron Healthcare Solutions, INC. | $39.58 | 2024 | Dupixent |
| Travere Therapeutics, INC. | $38.70 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $34.69 | 2019-2024 | Farxiga |
| Tms Neurohealth Centers INC. | $16.67 | 2025 | Tms Neurohealth Centers INC. |
| Amgen INC. | $15.16 | 2025 | Tavneos |
| Akebia Therapeutics INC | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Alamir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.